Last reviewed · How we verify
Salvage antiretroviral therapy including raltegravir
Salvage antiretroviral therapy including raltegravir is a Integrase strand transfer inhibitor (INSTI) Small molecule drug developed by Germans Trias i Pujol Hospital. It is currently FDA-approved for HIV-1 infection in treatment-experienced patients with integrase inhibitor-naive status (salvage therapy). Also known as: RAL.
Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.
Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-experienced patients with integrase inhibitor-naive status (salvage therapy).
At a glance
| Generic name | Salvage antiretroviral therapy including raltegravir |
|---|---|
| Also known as | RAL |
| Sponsor | Germans Trias i Pujol Hospital |
| Drug class | Integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the catalytic activity of HIV integrase, an enzyme essential for viral replication. By preventing integration of viral DNA into the host genome, it stops the establishment of productive HIV infection. This mechanism is particularly valuable in treatment-experienced patients with drug-resistant HIV, as it represents a distinct class from nucleoside/nucleotide reverse transcriptase inhibitors and protease inhibitors.
Approved indications
- HIV-1 infection in treatment-experienced patients with integrase inhibitor-naive status (salvage therapy)
Common side effects
- Diarrhea
- Nausea
- Headache
- Insomnia
- Elevated creatine kinase
Key clinical trials
- HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain (PHASE4)
- Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salvage antiretroviral therapy including raltegravir CI brief — competitive landscape report
- Salvage antiretroviral therapy including raltegravir updates RSS · CI watch RSS
- Germans Trias i Pujol Hospital portfolio CI
Frequently asked questions about Salvage antiretroviral therapy including raltegravir
What is Salvage antiretroviral therapy including raltegravir?
How does Salvage antiretroviral therapy including raltegravir work?
What is Salvage antiretroviral therapy including raltegravir used for?
Who makes Salvage antiretroviral therapy including raltegravir?
Is Salvage antiretroviral therapy including raltegravir also known as anything else?
What drug class is Salvage antiretroviral therapy including raltegravir in?
What development phase is Salvage antiretroviral therapy including raltegravir in?
What are the side effects of Salvage antiretroviral therapy including raltegravir?
What does Salvage antiretroviral therapy including raltegravir target?
Related
- Drug class: All Integrase strand transfer inhibitor (INSTI) drugs
- Target: All drugs targeting HIV integrase
- Manufacturer: Germans Trias i Pujol Hospital — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-experienced patients with integrase inhibitor-naive status (salvage therapy)
- Also known as: RAL
- Compare: Salvage antiretroviral therapy including raltegravir vs similar drugs
- Pricing: Salvage antiretroviral therapy including raltegravir cost, discount & access